Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 654

1.

Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.

Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.

Clin Cancer Res. 2019 Jul 1;25(13):4194. doi: 10.1158/1078-0432.CCR-19-1601. No abstract available.

PMID:
31263033
2.

Management of metastatic cutaneous melanoma: updates in clinical practice.

Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC.

Ther Adv Med Oncol. 2019 May 22;11:1758835919851663. doi: 10.1177/1758835919851663. eCollection 2019. Review.

3.

Commentary: To OAC or not to OAC? That is the question.

Atkins M, Reardon MJ.

J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31099-2. doi: 10.1016/j.jtcvs.2019.04.103. [Epub ahead of print] No abstract available.

PMID:
31204140
4.

Commentary: Constant variability.

Atkins M, Reardon MJ.

J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31098-0. doi: 10.1016/j.jtcvs.2019.04.102. [Epub ahead of print] No abstract available.

PMID:
31204136
5.

Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women.

Mays D, Ahn J, Zhang B, Atkins MB, Goerlitz D, Tercyak KP.

Ann Behav Med. 2019 Jun 11. pii: kaz021. doi: 10.1093/abm/kaz021. [Epub ahead of print]

PMID:
31185074
6.

Magnetic Human Corneal Endothelial Cell Transplant: Delivery, Retention, and Short-Term Efficacy.

Xia X, Atkins M, Dalal R, Kuzmenko O, Chang KC, Sun CB, Benatti CA, Rak DJ, Nahmou M, Kunzevitzky NJ, Goldberg JL.

Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2438-2448. doi: 10.1167/iovs.18-26001.

7.

A Job Well Begun Is Half Done.

Atkins MD, Reardon MJ.

Semin Thorac Cardiovasc Surg. 2019 May 21. pii: S1043-0679(19)30077-2. doi: 10.1053/j.semtcvs.2019.02.017. [Epub ahead of print] No abstract available.

PMID:
31125605
8.

The promise of Immuno-oncology: implications for defining the value of cancer treatment.

Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD.

J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0.

9.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
10.

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.

White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C.

Dev Cell. 2019 May 6;49(3):425-443.e9. doi: 10.1016/j.devcel.2019.04.014.

PMID:
31063758
11.

Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies.

Mair B, Tomic J, Masud SN, Tonge P, Weiss A, Usaj M, Tong AHY, Kwan JJ, Brown KR, Titus E, Atkins M, Chan KSK, Munsie L, Habsid A, Han H, Kennedy M, Cohen B, Keller G, Moffat J.

Cell Rep. 2019 Apr 9;27(2):599-615.e12. doi: 10.1016/j.celrep.2019.02.041.

12.

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2019 Apr 3;6(4):ofz142. doi: 10.1093/ofid/ofz142. eCollection 2019 Apr.

13.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
14.

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.

Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.

15.

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.

Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P, Parks JM, Cooper SJ, Wagner D, Zeck JC, Charabaty AJ, Atkins MB.

J Immunother Cancer. 2019 Mar 4;7(1):61. doi: 10.1186/s40425-019-0533-0.

16.

Collaboration with Urban Community Stakeholders: Refining Paraprofessional-led Services to Promote Positive Parenting.

Mehta TG, Lakind D, Rusch D, Walden AL, Cua G, Atkins MS.

Am J Community Psychol. 2019 Jun;63(3-4):444-458. doi: 10.1002/ajcp.12316. Epub 2019 Mar 1.

PMID:
30825221
17.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

PMID:
30779531
18.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
19.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
20.

Choice of first-line therapy in metastatic melanoma.

Gibney GT, Atkins MB.

Cancer. 2019 Mar 1;125(5):666-669. doi: 10.1002/cncr.31774. Epub 2019 Jan 29. No abstract available.

PMID:
30695110
21.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
22.

Drosophila Genetics: The Power of Genetic Mosaic Approaches.

Atkins M.

Methods Mol Biol. 2019;1893:27-42. doi: 10.1007/978-1-4939-8910-2_2.

PMID:
30565122
23.

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.

Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.

Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.

24.

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2018 Oct 5;5(10):ofy251. doi: 10.1093/ofid/ofy251. eCollection 2018 Oct. Erratum in: Open Forum Infect Dis. 2019 Apr 03;6(4):ofz142.

25.

Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes.

Hanson HA, Hay WW Jr, Tobin JN, Barkin SL, Atkins M, Karagas MR, Dozier AM, Wetmore C, Konstan MW, Heubi JE.

J Clin Transl Sci. 2018 Jun;2(3):156-162. doi: 10.1017/cts.2018.29.

26.

Risk Perceptions for Trauma-Related Research: An Exploratory Study of Undergraduate Student Researchers in Psychology.

Atkins MS, LeGrow C.

J Empir Res Hum Res Ethics. 2018 Dec;13(5):537-545. doi: 10.1177/1556264618805282. Epub 2018 Oct 25.

PMID:
30358480
27.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
28.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
29.

Modulation of the Hippo pathway and organ growth by RNA processing proteins.

Mach J, Atkins M, Gajewski KM, Mottier-Pavie V, Sansores-Garcia L, Xie J, Mills RA, Kowalczyk W, Van Huffel L, Mills GB, Halder G.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10684-10689. doi: 10.1073/pnas.1807325115. Epub 2018 Sep 26.

30.

Community Health Workers and Social Proximity: Implementation of a Parenting Program in Urban Poverty.

Gustafson EL, Atkins M, Rusch D.

Am J Community Psychol. 2018 Dec;62(3-4):449-463. doi: 10.1002/ajcp.12274. Epub 2018 Sep 17.

PMID:
30222866
31.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.

PMID:
30191365
32.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.

33.

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Atkins MB, Tannir NM.

Cancer Treat Rev. 2018 Nov;70:127-137. doi: 10.1016/j.ctrv.2018.07.009. Epub 2018 Jul 20. Review.

34.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2019 Feb;29(1):70-76. doi: 10.1097/CMR.0000000000000483.

PMID:
30169431
35.

Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI).

Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, Heckner M, Bax JJ, Fang XM, Grove EL, Lesser J, Maurovich-Horvat P, Otton J, Shin S, Pontone G, Marques H, Chow B, Nomura CH, Tabbalat R, Schmermund A, Kang JW, Naoum C, Atkins M, Martuscelli E, Massberg S, Hausleiter J; PROTECTION VI investigators.

Eur Heart J. 2018 Nov 1;39(41):3715-3723. doi: 10.1093/eurheartj/ehy546.

PMID:
30165629
36.

A qualitative study to explore paraprofessionals' role in school-based prevention and early intervention mental health services.

Rusch D, Walden AL, Gustafson E, Lakind D, Atkins MS.

J Community Psychol. 2019 Mar;47(2):272-290. doi: 10.1002/jcop.22120. Epub 2018 Aug 30.

37.

The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models.

Vicente C, Stirparo R, Demeyer S, de Bock CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA, Cools J.

J Hematol Oncol. 2018 Aug 25;11(1):108. doi: 10.1186/s13045-018-0650-0.

38.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

39.

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.

Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration.

JNCI Cancer Spectr. 2018 Jul;2(3):pky021. doi: 10.1093/jncics/pky021. Epub 2018 Jul 19. Review.

40.

Implementation of an Enhanced Recovery After Surgery Program Can Change Nutrition Care Practice: A Multicenter Experience in Elective Colorectal Surgery.

Martin L, Gillis C, Atkins M, Gillam M, Sheppard C, Buhler S, Hammond CB, Nelson G, Gramlich L.

JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):206-219. doi: 10.1002/jpen.1417. Epub 2018 Jul 23.

PMID:
30035814
41.
42.

Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.

Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A.

J Immunother. 2018 Sep;41(7):332-335. doi: 10.1097/CJI.0000000000000239.

PMID:
29965858
43.

Teacher Job Stress and Satisfaction in Urban Schools: Disentangling Individual-, Classroom-, and Organizational-Level Influences.

Ouellette RR, Frazier SL, Shernoff ES, Cappella E, Mehta TG, Maríñez-Lora A, Cua G, Atkins MS.

Behav Ther. 2018 Jul;49(4):494-508. doi: 10.1016/j.beth.2017.11.011. Epub 2017 Dec 16.

44.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29867230
45.

The transcription factor Grainy head primes epithelial enhancers for spatiotemporal activation by displacing nucleosomes.

Jacobs J, Atkins M, Davie K, Imrichova H, Romanelli L, Christiaens V, Hulselmans G, Potier D, Wouters J, Taskiran II, Paciello G, González-Blas CB, Koldere D, Aibar S, Halder G, Aerts S.

Nat Genet. 2018 Jul;50(7):1011-1020. doi: 10.1038/s41588-018-0140-x. Epub 2018 Jun 4.

46.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

47.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
48.

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.

Diana P, Mankongpaisarnrung C, Atkins MB, Zeck JC, Charabaty A.

ACG Case Rep J. 2018 Feb 28;5:e17. doi: 10.14309/crj.2018.17. eCollection 2018.

49.

Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Tannir NM, Pal SK, Atkins MB.

Oncologist. 2018 May;23(5):540-555. doi: 10.1634/theoncologist.2017-0534. Epub 2018 Feb 27. Review.

50.

Correction to: The Effect of a Change Agent on Use of Evidence-Based Mental Health Practices.

Leathers SJ, Spielfogel JE, Blakey J, Christian E, Atkins MS.

Adm Policy Ment Health. 2018 May;45(3):518. doi: 10.1007/s10488-018-0859-9.

PMID:
29478212

Supplemental Content

Loading ...
Support Center